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Abstract
Background: There are reports showing that l-carnitine alone or in combination with other micronutrients improve
sperm parameters. However, comparative studies are still lacking. This study was carried out to compare the short
term effects of a combination of eight micronutrients including l-carnitine vs. a mono-substance (l-carnitine alone)
on sperm parameters.
Methods: This was a prospective, open-labelled, nonrandomized study that included male subjects (20 to 60 years)
with at least 1 year of subfertility and at least one pathological semen analysis who received 3 months treatment
with a mono-substance (500 mg l-carnitine/twice a day, n = 156) or a combined compound (440 mg l-carnitine +
250 mg l-arginine + 40 mg zinc + 120 mg vitamin E + 80 mg glutathione + 60 μg selenium + 15 mg coenzyme Q10
+ 800 μg folic acid/once a day, n = 143) for the same time period. Sperm parameters were analyzed before and
after treatment and groups comparisons performed.
Results: Baseline characteristics were similar among studied groups (age and body mass indices). Semen
parameters (volume, density, overall progressive motility [including slow and fast motility]) and percentage
of sperm with normal morphology improved after 3 months in both groups as compared to baseline. However,
relative change (expressed as % increase of absolute values) for sperm density and overall progressive motility
(including fast motility) was found to be higher for the combined micronutrient treatment group as compared to
the mono-treatment using l-carnitine alone.
Conclusion: Both analyzed groups displayed a positive short term effect on all sperm parameters; however effect
on density and motility was significantly better for the combined formulation. There is need for more research in
this matter that includes long term outcome data.
Trial registration: Retrospectively registered at ISRCTN (7th October 2016). Study ID: ISRCTN48594239
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Background
At the peak of reproductive capability, a healthy couple
has an annual pregnancy probability rate of 80–85%.
Nevertheless, 10–15% of couples trying to achieve preg-
nancy remain childless [1]. Male factor accounts for
nearly half of cases of infertility presenting an abnormal
semen analysis. In 45% of sub-/infertile men, this dis-
order is of unexplained (unidentified) origin [2, 3].
Reports indicate that sperm quality has declined over
the past decades [4, 5]. Mainly, this fact seems to be the
result of certain nutritional deficiencies and adverse
environmental and lifestyle factors [6, 7]. Various micro-
nutrients [8–11] are directly or indirectly involved in
sperm metabolism; and nutrient deficiencies can lead to
impaired sperm quality [12, 13]. Ionising radiation, geni-
tal infections and alcohol, cigarette or illicit drug con-
sumption can cause intrinsic toxicity and generate
intense body oxidative stress. The negative impact of
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reactive oxygen species (ROS) has been recognized as a
main cause of idiopathic infertility [14, 15]. Free radicals
damage spermatic nuclear and mitochondrial genetic in-
formation producing strand breaks in the DNA [16, 17];
thus, impairing their mobility and morphology through
lipid peroxidation of the plasma membrane, and com-
promising sperm cell and oocyte interaction [18–20].
In a Cochrane review, it has been reported that anti-
oxidant supplementation in sub-fertile males may im-
prove the outcomes of live birth and pregnancy rate for
sub-fertile couples undergoing ART cycles [17]. The
suspected mechanism of action is the improvement of
sperm quality through the alleviation of the nutrient
deficiency as well as the reduction of oxidative stress [21].
The sum of these effects leads to a higher chance of preg-
nancy, an undisturbed intrauterine development and a
certain inherent protection of the newborn [22–33].
Previous studies have assessed the use of l-carnitine
alone as well as various combination therapies as an ef-
fective way of improving semen analysis results [34–42].
However, a direct contrast with a combination of various
micronutrients and, consequently, a quantification of the
effects, has not yet been assessed in the framework of a
research study. Hence, the aim of the present investiga-
tion was to compare the short term effect of a combin-
ation of eight micronutrients (including l-carnitine) vs. a
standard mono-substance (l-carnitine alone) on sperm
parameters.
Methods
This was a prospective, open-labelled, non-randomized
study that included male subjects consulting according
to inclusion criteria between January 2005 and January
2014 at the IMI Fertility Center and the Med19 Study
Center of Vienna, Austria.
A total of 299 participants who met inclusion criteria:
20 to 60 years of age, suffering from at least 1 year of
subfertility and had at least one recent pathological
semen analysis result (up to 3 months, considered base-
line) were invited to participate for 3 months to receive
treatment with a mono-substance (500 mg l-carnitine/
twice a day, n = 156) or a combined compound
(440 mg l-carnitine + 250 mg l-arginine + 40 mg zinc +
120 mg vitamin E + 80 mg glutathione + 60 μg selenium
+ 15 mg coenzyme Q10 + 800 μg folic acid/once a day,
n = 143; Profertil®, Lenus Pharma GmbH, Vienna,
Austria) for the same period of time. A second semen
analysis was performed after 3 months. Subjects were
encouraged to refrain from the consumption of other
micronutrients during the study period. Exclusion cri-
teria were: azoospermia, aspermia, varicocele, recent
urogenital infections, and hormonal disorders.
The following sperm parameters were analysed at
baseline and after treatment: sperm volume (ml) and
density (mio/ml), overall, fast and slow progressive mo-
tility (expressed as %), and % of sperm with normal
morphology. All parameters were defined according to
WHO guidelines (4th edition). Local ethical approval
was obtained for this study which was retrospectively
registered at ISRCTN (7th October 2016). Study ID:
ISRCTN48594239 www.isrctn.com. All subjects were in-
formed of the research, its objectives and provided
signed consent of participation and publication of indi-
vidual patient data. Pseudonymisation and access restric-
tions were used in order to avoid public access to the
sensitive patient data.
Statistical analysis was performed with the Statistical
Package for the Social Sciences version 22.0 (IBM SPSS,
Armonk, NY, USA). All data are presented as mean ±
standard deviations. The Kolmogorov Smirnov test was
used to assess the normality of data distribution. For
each measured variable and each case changes from
baseline (increase, decrease or none) were calculated as
absolute (subtraction of 3rd month value minus base-
line) or relative values (the percent expression of each
calculated absolute value). Paired Student’s T test was
used for intragroup comparisons. Non paired Student’s
T test or the Mann Whitney U test was used for inter-
group comparisons. A p value of <0.05 was considered
as statistically significant.
Results
Age ranged from 20 to 60 years in both groups, display-
ing similar median age and body mass indices. Other
baseline characteristics such alcohol and tobacco con-
sumption were similar among studied groups. The effect
of each treatment on semen parameters after 3 months
is presented in Table 1. It was observed that all studied
sperm parameters (volume, density, overall progressive
motility [including slow and fast motility]) and % of
sperm with normal morphology significantly improved
after 3 months of treatment in both groups as compared
to baseline. However, relative change (expressed as % in-
crease of absolute values) for sperm density and overall
progressive motility (including fast motility) was found
to be higher for the combined micronutrient treatment
group as compared to the mono-treatment group using
l-carnitine alone. Worth to note was the fact that the
baseline slow- and fast progressive motility and % of
normal morphology were significantly different between
studied groups.
Discussion
The effect of the administered mono-substance composed
of the hydrophile molecule l-carnitine can be ascribed to
its properties as a radical catcher in the mitochondrial
membrane. By substitution anti-oxidative capacity in the
seminal plasma increases significantly [43]. Moreover,
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Table 1 Semen parameters before and after 3 months according to each treatment group
Mono treatment n = 156 Combined treatment n = 143
Basal 3 months Absolute changea Relative change (%) b Basal 3 months Absolute changea Relative change (%) b
Sperm volume (ml) 3.0 ± 1.2 3.5 ± 1.5* 0.5 ± 1.6 35.2 ± 75.3 2.9 ± 1.2 3.6 ± 1.4* 0.7 ± 1.4 41.5 ± 74.3
Sperm density (mio/ml) 28.5 ± 19.0 34.2 ± 21.7* 5.7 ± 21.3 63.7 ± 158.0 24.9 ± 16.2 32.8 ± 20.0* 7.9 ± 23.5 157.7 ± 400.4**
Overall progressive motility (%) 35.7 ± 15.8 44.9 ± 19.9* 9.2 ± 18.6 44.0 ± 90.3 33.4 ± 14.6 48.6 ± 17.6* 15.2 ± 17.9** 80.3 ± 142.5**
fast progressive motility (%) 16.7 ± 10.6 23.0 ± 14.0* 6.3 ± 16.0 87.4 ± 184.0 10.3 ± 9.4** 20.4 ± 13.1* 10.1 ± 15.0** 259.3 ± 389.1**
slow progressive motility (%) 19.2 ± 12.7 22.2 ± 13.1* 2.9 ± 12.8 125.9 ± 384.9 23.1 ± 12.9** 28.3 ± 12.2*, ** 5.1 ± 12.7 102.9 ± 261.5
Normal morphology (%) 17.9 ± 14.0 27.5 ± 16.1* 9.6 ± 17.8 230.3 ± 668.1 26.2 ± 15.6** 35.9 ± 16.1*, ** 9.7 ± 19.4 307.1 ± 1,012.2
Data are presented as mean ± standard deviations
* p value < 0.001 as compared to basal as determined with the paired Student’s T test
** p value < 0.05 as compared to mono treatment as determined with the non paired Student’s T test
a Absolute change for each variable and case was calculated subtracting third month value minus basal one












studies in animals have shown that the molecule has pro-
tective effects on testicular tissue which has been exposed
to ionising radiation [44, 45]. This realisation can have a
relevant effect on sperm quality in certain daily situations.
Both effects serve as an explanation model for the positive
influence of l-carnitine on sperm concentration, motility
and morphology [34, 46, 47]. Consistent with these stud-
ies, our study found that l-carnitine alone or in combin-
ation with seven other micronutrients displayed short
term improvement of all studied sperm parameters.
Nevertheless, the combined preparation showed better
results through a higher percent increase for sperm
density and overall progressive motility (including fast
motility) as compared to l-carnitine alone. To the
best of our knowledge this research may be the first
to prospectively compare the short-term effects of a
mono treatment versus a combined product on sperm
parameters.
The effect of the combination substance is to be seen
as the sum of the partly augmentative effects of each
component. The water-soluble l-arginine has a positive
effect on sperm parameters such as motility and vitality
[48, 49]. The hydrophile coenzyme Q10 catches free
radicals, and improves male FSH and LH serum profile
[9, 50] and shows an improvement over sperm concen-
tration, motility and morphology [9, 51]. The hydrophile
dietary mineral zinc provides a protective antioxidant
effect during sperm production that may counteract
against copper excess [52, 53], improving sperm cell
concentration and motility [54–57]. Hydrophile folic
acid reduces the concentration of round cells in the
semen which are a major source for free radicals
[58, 59]; and hence leading to a reduction of oxida-
tive stress [60] as well as a rise in sperm cell con-
centration [61]. Furthermore, there is evidence that
folic acid could compensate for adverse influences of
hypothyroidism and thyrostatic substances on tes-
ticular tissue [62, 63]. Selenium reduces oxidative
stress [64] as it is bound as a structural element in
the sperm cell membrane in form of the enzymes
selenoprotein mGPx4 and snGPx4 [65]. Moreover, it
optimizes thyroid metabolism important for sperm
production and has a positive influence on auto-
immune processes [66]. Selenium intake improves
sperm motility [67] and morphology [65]. The water-
soluble glutathione reduces oxidative stress signifi-
cantly [68] which leads to an increase of progressive
and morphologically normal sperm cells [38].
Regarding oxidative stress, one study found that l-
carnitine improved sperm motility in asthenozoos-
permic men with normal levels of phospholipid
hydroperoxide glutathione peroxidase, an important
enzyme that minimizes oxidative stress [69]. The
liposoluble vitamin E as component of the human
cell membrane acts as oxidative protector for like-
wise located unsaturated fatty acids [70]. Vitamin E
supplementation reduces lipid peroxidation, therefore
improving sperm motility significantly [21]. This an-
tioxidative effect may potentiate the beneficial effects
of l-carnitine. Indeed, one study found that the com-
bination of l-carnitine (2 g per day) and vitamin E
improved sperm motility in asthenozoospermic men;
effect which was not observed among those taking
vitamin E alone [71].
L-carnitine seems not the sole actor in sperm produc-
tion. As already mentioned, the combined compound
displayed a better improvement of sperm density and
overall progressive motility. This is important because
motility seems to be a key parameter of male fertility.
The diverse target points for eight micronutrients and
their partially synergistic cooperation in different body
compartments serve as an explanatory model for its se-
lective superiority as compared to the mono-therapy
with l-carnitine alone. It is still unclear whether motility
improvement exerted by combined compound is due to
enhanced oxidative stress suppression or to the sum of
the specific singular effects of each compound.
Authors acknowledge that the study has limitations.
Indeed, although data is prospective, its open-labelled
and non-randomized nature is a potential source of bias.
On the other hand, this document does not present final
outcome of pregnancies; however, this was not the pri-
mary endpoint aim of this study arm. Data related to
outcome of pregnancy, as a secondary end-point, will be
presented elsewhere.
Despite these limitations, prospective comparative data
regarding the efficacy of mono-treatment and combined
compound on sperm parameters are lacking. Hence, this
may be seen as a potential strength of our study. Never-
theless, there is need for well controlled prospective ran-
domized data.
Conclusion
Overall effect on sperm parameters was similar in both
analyzed groups; however, in the combined-formulation
group improvement of sperm density, overall and fast
progressive motility was significantly better than those
in the mono-preparation group. There is a need for
more research in this matter that include pregnancy
outcome data.
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